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Abstract. – BACKGROUND: Candida blood-
stream infections (BSI) represent an important
problem in Intensive Care Units (ICUs). The epi-
demiology of candidemia is changing with an in-
crease in the proportion of Candida (C.) non-al-
bicans.
OBJECTIVES: An Italian 2-year observational
survey on ICU was conducted to evaluate the
species distribution and possible differences be-
tween BSI caused by C. albicans and C. non-albi-
cans. For comparative purposes, we performed a
European literature-based review to evaluate dis-
tribution and frequency of Candida spp. causing
ICU candidemia, during the period 2000-2013.
MATERIALS AND METHODS: This laboratory-
based survey involved 15 microbiology centers
(GISIA-3 study). All candidemia episodes in adult
patients were considered. Data were prospective-
ly collected from 2007 to 2008. PubMed was
searched for peer-reviewed articles.
RESULTS: In total, 462 candidemia episodes
were collected. C. albicans accounted for 49.4%
of the isolates, followed by C. parapsilosis
(26.2%) and C. glabrata (10.4%). Mortality was
higher in patients with C. non-albicans than C.
albicans (47.3% vs. 32.4 %, p > 0.05). Among
risk factors, parenteral nutrition was more com-
mon (p = 0.02) in non-albicans candidemia,
while surgery was more frequent (p = 0.02) in C.
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albicans candidemia. Twenty-four relevant arti-
cles were identified. C. albicans was the pre-
dominant species in almost all studies (range
37.9% -76.3%). C. glabrata was commonly iso-
lated in the German-speaking countries,
France, UK and North Europe; C. parapsilosis in
Turkey, Greece and Spain.
CONCLUSIONS: Although C. non-albicans
BSI is increasing, our study shows that C. albi-
cans is still the predominant species in ICU can-
didemia. There are differences in the epidemiol-
ogy of Candida BSI among European countries,
with a prevalence of C. glabrata and C. parap-
silosis in Northern and Southern countries, re-
spectively.
Key Words:
Yeast infections, Candidemia, Intensive Care Unit,
Literature review, Candida spp.
Introduction
Candida bloodstream infections (BSI) repre-
sent an important problem in critically ill patients
hospitalized in Intensive Care Units (ICUs). Can-
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In this study, we considered only patients older
than 18 years who developed candidemia, either
on admission or during their stay in the ICU. For
patients with multiple candidemic episodes, only
the first episode was included. Detection and
species identification of Candida isolates were
performed in the notifying laboratories according
to standard protocols in use in each laboratory. A
common dataset was used to collect data about
age, gender, reasons for ICU admission (medical,
surgical or trauma), predisposing risk factors for
Candida BSI [i.e. vascular lines (for > 3 days),
treatment with broad spectrum antibiotics (for >
5 days)] and outcome at 30 days after diagnosis].
At the time of study, informed consent was not
required because of the observational nature of
the surveillance.
Case identification
An episode of candidemia was defined as iso-
lation of Candida spp. from blood culture in a
patient with temporally related clinical signs and
symptoms. Subsequent positive cultures from the
same patient were defined as a new episode only
if there was an interval of ≥4 weeks between the
two episodes. According to diagnoses at the time
of ICU admission, patients were classified as sur-
gical, trauma, or medical. Surgical patients were
those admitted in ICU for the postoperative con-
trol of an elective procedure, trauma patients
were those with trauma-related acute lesions, and
medical patients were those admitted for any oth-
er critical illness. A case was defined as likely to
be catheter related when (1) semi-quantitative
culture of the catheter tip yielded more than 15
CFU of a Candida species or (2) simultaneous
quantitative cultures of blood samples showed a
ratio of 5:1 in CFU of blood samples obtained
through the catheter and a peripheral vein.
Statistical Analysis
SAS system version 9.2 was used for statisti-
cal analysis. Categorical variables were given as
number and percentages. The Chi-square test was
used to evaluate the difference in prevalence be-
tween CA and CnA. Kaplan-Meier survival
curves and log-rank test results were performed
for survival comparisons between CA and CnA
candidemia groups. A p-value <0.05 was consid-
ered significant.
Literature Review Criteria
A review of full-text articles published in Eng-
lish from January 2000 to February 2013 was
dida BSI is often a consequence of the use of
complex surgical procedures, invasive medical
devices, and/or long term broad spectrum antibi-
otic therapy1. The Extended Prevalence of Infec-
tion in Intensive Care (EPIC II) survey, which in-
cluded 14,414 patients from 1265 ICUs across 75
countries, provided an up-to date picture of the
prevalence, treatment, and outcomes of ICU in-
fections2-3. A subgroup analysis of the BSI data,
recorded a prevalence of 6.9 candidemia cas-
es/1000 patients, and showed that candidemia
was associated with the highest mortality rate
(43%) of all BSIs2. Invasive Candida infections
are associated with prolonged hospital stays and
increased costs of medical care4. Although C. al-
bicans (CA) is still the most common species2,5,
recent epidemiological studies have demonstrat-
ed an increasing incidence of C. non-albicans
(CnA) candidemia among critically ill patients6.
Generally, C. glabrata, C. parapsilosis, C. tropi-
calis and C. krusei represent about one half of all
cases of candidemia, with C. glabrata ranked as
second in the USA, Northern Europe and Aus-
tralia7-9, while C. parapsilosis is the most rele-
vant non-albicans species in Latin America and
Southern Europe10-12.
In Italy, national epidemiological data on Can-
dida BSI in critically ill patients are lacking13: re-
cent epidemiological studies are limited to select-
ed hospitals or a specific region14-16. Therefore,
we conducted a 2-year large observational Italian
survey on candidemia in ICU to evaluate the
species distribution and to identify possible dif-
ferences between BSI due to CA and CnA. For
comparative purposes, we performed a literature
based review of European studies concerning the
distribution and the frequency of Candida spp.
causing BSI in adult ICU patients, during the pe-
riod 2000 to 2013.
Materials and methods
Design of the study
This study was performed in the context of the
GISIA-3 study, designed as a prospective, obser-
vational nationwide laboratory-based survey from
January 2007 to December 2008. This investiga-
tion involved 15 Microbiology Centers distributed
all over Italy and representative of the country.
The primary aim of GISIA-3 was to characterize
the freshly isolated yeast strains in terms of their
in vitro susceptibility to systemic antifungal drugs
available in Italy at the time of the study17.
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Total C. albicans C. non-albicans
Characteristics# n. 462 n. 228 (49.4)§ n. 234 (50.6)§
Age
18-50 202 (43.7) 110 (48.2) 92 (39.3)
51-99 260 (56.3) 118 (51.8) 142 (60.7)
Male 281 (60.8) 139 (61.0) 142 (60.7)
Admission service
Medical 191 (41.3) 87 (38.2) 104 (44.4)
Surgery* 210 (45.5) 116 (50.9) 94 (40.2)
Trauma 61 (13.2) 25 (11.0) 36 (15.4)
Central venous catheterization 412 (89.2) 209 (91.7) 203 (86.7)
Antibacterial therapy 282 (61.0) 145 (63.6) 137 (58.5)
Total parenteral nutrition* 254 (55.0) 113 (49.6) 141 (60.2)
Diabetes mellitus 44 (9.5) 26 (11.4) 18 (7.7)
Solid neoplastic tumor 28 (6.1) 10 (4.4) 18 (7.7)
Corticotherapy 26 (5.6) 9 (3.9) 17 (7.3)
Burns 21 (4.5) 9 (3.9) 12 (5.1)
Hematological malignancy 19 (4.1) 5 (2.2) 14 (6.0)
performed. Four of the authors (MTM, GM, GL,
EB) independently performed the literature
search to judge the contents of the articles sepa-
rately; disagreement in opinion about evaluations
was solved by discussion.
The MEDLINE database was used for the bibli-
ographic research, using the following key words:
“candidemia”, “Candida epidemiology”, “can-
didemia intensive care unit”, “Candida intensive
care unit” and “fungemia”. In addition, the bibli-
ographies of the selected articles were reviewed
for relevant publications. The exclusion criteria
were: studies carried out prior to year 2000, letters
and randomized controlled trials, and studies re-
porting a total number of Candida spp. isolates
less than ten. From each selected study, the fol-
lowing data were collected: geographic location,
year of publication, study period, type of study, to-
tal number of isolated Candida spp., and relative
proportion of each Candida spp. In addition, if da-
ta were available, the risk factors for CA and CnA
candidemia in the ICU were analyzed.
Results
Prospective Analysis of Cases in Italy
The surveillance identified 462 cases of can-
didemia. CA was isolated with the highest fre-
quency (49.4%); C. parapsilosis ranked second
(26.2%), followed by C. glabrata (10.4%), C.
tropicalis (6.5%), C. krusei (2.8%), C. guillier-
mondii (1.5%), C. lusitaniae (1.3%), C. lipolytica
(0.6%) and C. famata, C. sake, C. utilis (0.4%,
each one). Sixty-one percent of the patients were
men and the highest frequency of candidemia oc-
curred in patients aged >51 years (56.3%). A to-
tal of 412 patients had central lines in situ at the
onset of candidemia. Catheters were studied for
the source of infection in 249 cases: 196 (78.7%)
were likely catheter associated. Most patients had
undergone a surgical procedure (45.5%). In this
group, gastrointestinal surgery was predominant
(53.8%), followed by cardiac surgery (23.3%).
Surgical patients were more likely to develop CA
than CnA candidemia (50.9 % vs. 40.2%, p =
0.02). Parenteral nutrition was significantly more
frequent when candidemia was due to CnA than
when it was due to CA (60.2% vs. 49.6%, p =
0.02) (Table I).
Data on outcome was available for 201 pa-
tients: 79 (39.3%) died within 1 month after on-
set of candidemia. Figure 1 presents the Kaplan-
Meier survival curves of patients with CA and
CnA candidemia: the p-value of the log-rank test
was 0.492.
Literature Review
A literature search to identify Candida species
responsible of candidemia was performed. Com-
parison of data among studies should be compro-
mised by differences in case definitions and data
collection methods. The studies cited in this re-
view were, therefore, chosen to provide only a
663
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Table I. Characteristics of ICU patients with candidemia, Italy 2007-2008.
#More than one factor may be present in a single case; *Statistically significant p-value (< 0.05); §Numbers in parentheses, percent.
Figure 1. Kaplan Meier curves for survival time in ICU
patients with Candida albicans (solid line) and Candida
non-albicans candidemia (dash line); Log rank test, p =
0.4922.
C. albicans
Candida non-albicans
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broad overview of the European epidemiology of
candidemia.
We selected a total of 24 articles (Table II). In
21 studies, CA was the most common species: in
17 articles it accounted for 51.3% to 76.3% of all
Candida infections13,18-33, and in four studies
from southern European countries, the proportion
of CA was between 37.9% and 49%14,16,34-35. In
the remaining three studies, the proportion of CA
was extremely low. In two studies conducted in
Turkey10,36, CA strains accounted for 18.6% and
22.9% of all Candida infections. In a survey
from Greece12, CA and C. parapsilosis were al-
most equally distributed (33.3% and 36.4%, re-
spectively).
Regarding CnA, the three most prevalent
species were C. glabrata, C. parapsilosis and C.
tropicalis.
Candida glabrata was prevalent in studies
from German-speaking countries, France, UK,
and North Europe, reaching proportions of 13.2-
31.2%19,21-23,26-28,30-31,33. Candida parapsilosis
emerged as an important opportunistic fungal
pathogen in the Mediterranean area: Turkey
(77.1%), Italy (37%), Greece (36.4%) and Spain
(28.8%)12,16,35-36. In contrast, C. parapsilosis was
a less common cause of candidemia in recent
surveys from France30 and Denmark19 (0% and
2.6%, respectively).
Candida tropicalis was, in general, less preva-
lent. It was the fourth most common species of
Candida in German-speaking countries, France,
Italy and Polish13,20-22,27-29,31, and the second in
Portugal34 and in Turkey10,25, accounting for
21.2% and 12.7% of all Candida BSIs, respec-
tively.
Table III lists the association of CA and CnA
candidemia with risk factors as reported in five
out of the 24 studies of candidemia considered
for analysis. Four studies did not find any differ-
ence when examining central venous catheter
(CVC) placement or glucocorticosteroid thera-
py14,24,26,28: in only one study24 was CnA can-
didemia independently associated with CVC and
significantly associated with glucocorticosteroid
therapy on multivariate analysis. In addition,
Holley et al26 found the duration of CVC place-
ment to be predictive for a CnA BSI. Four stud-
ies examined surgery14,16,26,28 and diabetes melli-
tus16,24,26,28; in only one study16, diabetes was as-
sociated with a four-fold increased risk of devel-
oping CA BSI and abdominal surgery two-fold,
compared to CnA BSI.
The issue of antifungal prophylaxis is ad-
dressed by all five studies. In this Italian study16,
previous exposure to azole drugs reduced the risk
of CA infection. In another Italian surveillance
report14, an increase in the proportion of CnA
was associated with increasing use of flucona-
zole prophylaxis (from 21% to 76% between
2000 and 2003). In one of the studies24, the dif-
ference in mortality between CnA and CA was
statistically significant using multivariate analy-
sis, showing an odds ratio of 6.7 for lethal out-
come in ICU patients with CnA, compared with
CA candidemia. A number of other risk factors
(neutropenia, parenteral nutrition, solid tumor
and duration of mechanical ventilation) were sig-
nificantly associated with the occurrence of CnA
infections, but only on univariate analysis.
Discussion
Invasive candidiasis is the most frequent life-
threatening fungal disease in ICU patients3 , and
candidemia represents more than two thirds of all
invasive cases8. Candida albicans is the domi-
nant species causing BSIs2 , and in most series it
remains close to 50%37-38.
In our data, CA was the leading fungal
pathogen, accounting for 49% of Candida BSIs;
this figure is in agreement with frequencies re-
ported from other European countries34-35. Over
the last two decades, an increase in the propor-
tion of CnA bloodstream isolates has been re-
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Author Horasan et al. 2010 Dizbay et al. 201036 Das et al. 201123
Country/Period of design Turkey Turkey UK
observation 2004-2009 2007 2005-2008
Study design/setting Retrospective cohort Prospective laboratory-based Prospective observational
study/single university study/single tertiary study/single tertiary
hospital - medical-surgical, hospital – surgical, anesthesiology, hospital - ? ICU and wards
ICU internal, medicine, neurology ICUc
No. Isolatesa 118d 35 55
C. albicans 18.6 22.9 52.7
C. parapsilosis 66.1 77.1 16.4
C. glabrata 2.5 — 21.8
C. tropicalis 12.7 — —
C. krusei — — —
C. kefyr — — —
C. dubliniensis — — —
C. famata — — —
C. guilliermondii — — —
C. intermedia — — —
C. lipolytica — — —
C. lusitaniae — — —
C. norvegensis — — —
C. sake — — —
C. utilis — — —
Candida spp.b — — 9.1
Table II. Distribution of Candida spp. from bloodstream infections in ICU patients, Europe 2000-2013.
%
o
f
is
o
la
te
s
ported in critically ill adults, and in some ICUs it
has been higher than 50%37-38. Similarly, we also
found a slightly higher percentage of CnA (51%)
than CA. The reason for this increase in CnA is
not yet completely understood. It is possible that
prophylaxis with fluconazole plays an important
role7,9,14 . However, a recent study of ICU patients
shows that prophylaxis with fluconazole did not
increase the proportion of invasive candidiasis
caused by CnA39. On the other hand, the increase
in CnA, may, at least in part, reflect a more accu-
rate identification of yeast isolates at the species
level. Yet, we cannot exclude the possibility that
an ever-increasing number of previously non-
pathogenic species are now emerging as oppor-
tunistic pathogens related to the increased num-
ber of immunocompromised subjects40.
In our work, as well as those selected from lit-
erature, C. parapsilosis, C. glabrata and C. trop-
icalis account for around 80% of all CnA can-
didemia. In addition, a variation in the distribu-
aRefers to the total number of Candida isolates from blood (or to the total number of candidemia episodes where the former
was not available from the original study). bIncludes Candida spp. not depicted in the table and Candida spp. not identified to
species level. cNon-neutropenic critically ill patients. dPatients staying 48 h or more after ICU admission. eNo fungal coloniza-
tion. fThe results for this study cover two countries. ?Data were not available.
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tion of these three Candida species results
throughout the Europe, with a north-south drift.
Candida glabrata was the second most common
species recovered in German-speaking countries,
France, UK, and North Europe19,21-23,26-28,30-31,33
while in Greece, Italy, Polish and Spain it ranked
number 312-14,20,24,29,32,35. Candida parapsilosis has
emerged as an important opportunistic fungal
pathogen in Turkey accounting for 66.1% to
77.1% of all Candida BSIs10,36. The lowest pro-
portion was reported in France30 and Denmark19.
The proportion of C. tropicalis was generally low
in all geographic region except in Portugal34 and
Turkey10,25 where it ranked second. In addition to
the difference across countries, there are also
variations within the same country. Proportions
of C. parapsilosis candidemia in Greek hospitals
ranged from 36.4% to 5.4%12,24 .
This variability may reflect differences in
health care practices among different countries,
as well as the study design adopted by different
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authors, including differences in the examined
population and the case definition. In our expe-
rience, C. parapsilosis was the second most
common species, responsible for roughly a
quarter of all candidemia episodes, according to
data from studies carried out in South Eu-
rope16,24-25,35. However, differences were ob-
served when we considered the Italian regions;
the proportions of C. parapsilosis and C.
glabrata varied from North to South, but only
C. glabrata isolation showed a statistically sig-
nificant difference (p < 0.001)17 .
Concerning risk factors, the most commonly
recognized risk factors were: number of antibi-
otics received prior to candidemia development;
isolation of Candida spp. from sites other than
blood; previous hemodialysis; prior use of a
Hickman catheter; recent extensive gastro-ab-
dominal surgery, and length of ICU stay. Several
risk factors were likely to be combined in indi-
vidual patients. Furthermore, some subsets of
ICU patients were at particular risk for can-
didemia, such as those with peritonitis, acute
pancreatitis, neutropenia, or cancer patients ex-
posed to chemotherapy37,41-43.
Our data from GISIA-3 study are in agreement
with above-mentioned studies. In addition, ac-
cording to other authors44, 78.7% of analyzed
catheters should be considered a source of Can-
dida BSI, highlighting the relevance of catheter-
related candidemia. Candidemia associated with
intravenous lines is problematic since these de-
vices act as substrates for production of biofilm,
which shows resistance to immunological effec-
tor mechanisms and to the activity of antifungal
agents45.
Few studies are available on the differences in
the risk factors between CA and CnA BSIs in
ICU patients. Some authors do not identify any
differences46, while our literature review high-
lights contradictory results. In fact, many poten-
tial risk factors for CnA BSI have been found
(presence of CVCs, duration of CVC implanta-
tion, corticotherapy, female gender, neutropenia,
receipt of parenteral nutrition, presence of solid
tumor, and duration of mechanical ventilation),
but no clinical factors appeared sufficiently perti-
nent to guide the choice of empirical antifungal
therapy.
GISIA-3 data highlights an association be-
tween parenteral nutrition and CnA, and the high
proportion of C. parapsilosis may explain this
finding. Parenteral nutrition facilitates C. parap-
silosis disease, since the yeast possesses a selec-
tive growth advantage in hyperalimentation solu-
tions with high concentrations of glucose47. Con-
versely, surgery resulted more frequently in CA
infection, although other authors do not consider
surgery a particular risk factor for CA can-
didemia development9,22.
It is well known that Candida BSIs affect the
survival of ICU patients. The EPIC II2 reported
that patients with candidemia, compared with
patients with Gram-positive and Gram-negative
infections, have the greatest crude ICU mortali-
ty (42.6%, 25.3%, and 29.1%, respectively). In
this study, we had these data available only for
201 patients, the 30-day mortality rate was
39.3%, similar to that reported in previous re-
searches16,20,29. Our finding supports that mortal-
ity associated with candidemia has not changed
substantially in the past two decades, despite
the availability of less toxic and more active an-
tifungal agents. Although an increased mortality
was reported in patients with CnA BSI24, this
relationship is not documented by other au-
thors16,26. In our study, mortality rate was higher
in patients with CnA compared with CA BSIs
(47.3% vs. 32.4%, respectively), although the
survey analysis was not statistically significant.
As GISIA-3 was an observational laboratory-
based survey, our study has some limitations: (1)
severity of illness scores was not obtained; (2)
we did not have data on the type and duration of
antifungal therapy; (3) data on mortality associat-
ed with candidemia were not available.
Nevertheless, this study shows that CA re-
mains the predominant species in ICU can-
didemia and CnA BSI is increasing. In addition,
our results reinforce the fact that candidemia
plays an important role in ICU patients treated
with indwelling devices and that Candida BSI is
associated with high mortality. Our review re-
veals a geographic variation among cases of can-
didemia in different parts of the Europe, with a
north-south drift, showing an increasing of C.
glabrata in northern countries, and of C. parap-
silosis in southern countries.
Conclusions
These data demonstrate that physicians should
base their antifungal choices on local epidemiol-
ogy. It is, therefore, important periodically to de-
termine the distribution of Candida spp. in each
institution, especially when empirical therapy is
common practice.
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